Deuterated Pyridazine Carboxamide Synthesis With Higher Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide are inefficient, with low yields and lengthy sequences, making them unsuitable for pharmaceutical applications.
Innovation Solution
A series of optimized synthetic steps involving specific reactions with activating reagents, bases, transition metal catalysts, and coupling agents, such as palladium catalysts and phosphine ligands, are employed to streamline the synthesis, improving yield and throughput.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing synthesis processes are used, then the synthesis can be performed with conventional methods, but the yields are low and the sequence is lengthy
Solution Approach 1:
The synthesis process is divided into discrete, optimized segments including: (a) reacting compound 1a with activating reagents to form Compound 2a, (b) treating with aqueous base to form Compound 3a, (c) coupling with Compound 7 to form Compound 8a, (d) Pd-catalyzed coupling with Compound 10 to form Compound 9a, and (e) final coupling with Compound 13 to form Compound I. Each segment is independently optimized for yield and time, transforming a lengthy conventional sequence into an efficient multi-step process with overall yield exceeding 50%.
Solution Approach 2:
The patent applies parameter changes by selecting specific reaction conditions for each synthesis step: using POCl3 as activating reagent, employing LiBr/DIPEA in water-acetonitrile mixture, using zinc acetate in water-2-propanol, applying Pd catalyst with phosphine ligand and dual-base system (K2CO3/DBU), and using EDC coupling agent. These parameter optimizations collectively improve both yield and cycle time, achieving high-quality Compound I suitable for pharmaceutical use.
2Quantity of substance
If existing synthesis processes are used, then the process can be performed with standard procedures, but the yields are low
Solution Approach 1:
The patent employs preliminary action by pre-optimizing each synthesis step with specific reagents and conditions before final execution. For example, Compound 7 is prepared in advance through a three-step sequence (condensation, nitration, reduction), and deuterated methylamine (Compound 13) is prepared beforehand. This preliminary preparation allows the main synthesis sequence to proceed efficiently with high yields, as each component is ready for optimal coupling.
Solution Approach 2:
The patent uses intermediary compounds and reagents to facilitate high-yield transformations. Key intermediaries include: Compound 3a (carboxylic acid or salt) as intermediate between activation and coupling, Compound 8a (activated ester) as intermediate for Pd-catalyzed coupling, and Compound 9a as intermediate before final amidation. These intermediaries are stabilized and isolated in high purity, enabling subsequent steps to proceed with excellent yields and facilitating pharmaceutical-grade manufacturing.
3Manufacturing precision
If the synthesis is optimized for yield, then high-quality Compound I is achieved, but the process complexity increases
Solution Approach 1:
The patent maintains continuity of useful action by designing a seamless multi-step synthesis where each reaction flows into the next without unnecessary interruptions. The process continues from Compound 1a through five main transformation steps to Compound I, with each step optimized to maintain high purity and yield. Continuous monitoring and controlled progression through each reaction stage ensure pharmaceutical-grade quality while managing process complexity through systematic organization.
Solution Approach 2:
The patent replaces conventional mechanical separation and purification methods with chemically selective transformations. For example, Pd-catalyzed cross-coupling provides high regioselectivity, reducing the need for complex separation steps. EDC-mediated amidation proceeds with high chemoselectivity, minimizing side products. These chemical selectivities substitute for mechanical purification complexity, achieving high manufacturing precision through molecular-level control rather than physical separation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved process achieves high-quality Compound I with enhanced yields and reduced cycle time, suitable for pharmaceutical use as a Tyk2 inhibitor for treating auto-immune and auto-inflammatory diseases.
Implementation Method 1
reacting Compound 8 with Compound 10 of the formula in the presence of a suitable transition metal catalyst, a ligand, one or more bases, and one or more suitable solvents to afford Compound 9a
Implementation Method 2
reacting Compound 9 with EDC or other coupling agents and Compound 13 of the formula to afford final product Compound I
Data Source
AI summary
The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula:Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.